207 related articles for article (PubMed ID: 19966210)
1. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.
Condomines M; Veyrune JL; Larroque M; Quittet P; Latry P; Lugagne C; Hertogh C; Kanouni T; Rossi JF; Klein B
J Immunol; 2010 Jan; 184(2):1079-84. PubMed ID: 19966210
[TBL] [Abstract][Full Text] [Related]
2. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
5. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Caraux A; Vincent L; Bouhya S; Quittet P; Moreaux J; Requirand G; Veyrune JL; Olivier G; Cartron G; Rossi JF; Klein B
Oncotarget; 2012 Nov; 3(11):1335-47. PubMed ID: 23154454
[TBL] [Abstract][Full Text] [Related]
6. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
7. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Minnie SA; Hill GR
Front Immunol; 2021; 12():651288. PubMed ID: 33777050
[TBL] [Abstract][Full Text] [Related]
8. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
9. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
10. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Derman BA; Zha Y; Zimmerman TM; Malloy R; Jakubowiak A; Bishop MR; Kline J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940591
[TBL] [Abstract][Full Text] [Related]
12. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
[No Abstract] [Full Text] [Related]
13. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
[TBL] [Abstract][Full Text] [Related]
14. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
16. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian D; Mo CC; Landgren O; Richardson PG
Br J Haematol; 2020 Dec; 191(5):692-703. PubMed ID: 32501533
[TBL] [Abstract][Full Text] [Related]
17. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
18. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
Rapoport AP; Stadtmauer EA; Aqui N; Vogl D; Chew A; Fang HB; Janofsky S; Yager K; Veloso E; Zheng Z; Milliron T; Westphal S; Cotte J; Huynh H; Cannon A; Yanovich S; Akpek G; Tan M; Virts K; Ruehle K; Harris C; Philip S; Vonderheide RH; Levine BL; June CH
Clin Cancer Res; 2009 Jul; 15(13):4499-507. PubMed ID: 19509133
[TBL] [Abstract][Full Text] [Related]
19. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
20. Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
Kazandjian D; Landgren O
Clin Adv Hematol Oncol; 2019 Oct; 17(10):559-568. PubMed ID: 31730582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]